Pharmacogenetics and genomics: Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 5, 2001, Pages 484-492

  Furuta, Takahisa ^c   Shirai, Naohito ^a,b   Xiao, Fang ^a,b   Ohashi, Kyoichi ^a,b   Ishizaki, Takashi ^a,b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; DRUG METABOLITE; LANSOPRAZOLE; PROTON PUMP INHIBITOR; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; CYP2C19 PROTEIN, HUMAN; CYTOCHROME P450; DRUG DERIVATIVE; ENZYME INHIBITOR; MIXED FUNCTION OXIDASE; OMEPRAZOLE; PROTON PUMP; UNSPECIFIC MONOOXYGENASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC GROUP; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; STOMACH PH; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; GASTROESOPHAGEAL REFLUX; GENETICS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOMOZYGOTE; RANDOMIZED CONTROLLED TRIAL; SECRETION; STOMACH ACID;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOMOZYGOTE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PROTON PUMPS;

EID: 0035208525     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.119721     Document Type: Article

References (33)

1. Effect of 10 mg and 20 mg omeprazole daily on duodenal ulcer: Double-blind comparative trial
2. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine
3. A double blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: A multicentre trial
4. Rabeprazole in treatment of acid peptic diseases. Results of three placebo-control dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD)
5. + ATPase
6. +-ATPase: The site of action of omeprazole
7. Identification of the human P450 enzymes involved in lansoprazole metabolism
8. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status
9. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects
10. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans
11. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole
12. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
13. Effect of CYP2C19-genotypic differences on cure rates for Helicobacter pylori infection by a triple therapy with proton pump inhibitor, amoxicillin, and clarithromycin
14. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin
15. Cure of refractory duodenal ulcer and infection caused by Helicobacter pylori by high doses of omeprazole and amoxicillin in a homozygous CYP2C19 extensive metabolizer patient
16. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans
17. Identification of a new genetic defect responsible for the polymorphism of (S) mephenytoin metabolism in Japanese
18. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population
19. High-performance liquid chromatographic determination of lansoprazole and its metabolites in human serum and urine
20. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism
21. Symptomatic gastroesophageal reflux: Incidence and precipitating factors
22. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety
23. Persistent acid secretion during omeprazole therapy: A study of gastric acid profiles in patients demonstrating failure of omeprazole therapy
24. Effects of genotypic differences in CYP2C19 status on the cure rates for gastroesophageal reflux disease by lanosprazole
25. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors
26. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors
27. Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome
28. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world
29. Comparison of lansoprazole and famotidine on gastric acid inhibition during daytime and nighttime in different CYP2C19 genotype groups
30. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects
31. High dose dual PPI/AMPC therapy as a second line therapy after failure of eradication of H. pylori by usual PPI-based therapies
32. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents
33. The life and death of Helicobacter pylori